Cargando…
DNA-Binding Anticancer Drugs: One Target, Two Actions
Amsacrine, an anticancer drug first synthesised in 1970 by Professor Cain and colleagues, showed excellent preclinical activity and underwent clinical trial in 1978 under the auspices of the US National Cancer Institute, showing activity against acute lymphoblastic leukaemia. In 1984, the enzyme DNA...
Autores principales: | Baguley, Bruce C., Drummond, Catherine J., Chen, Ying Yi, Finlay, Graeme J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866126/ https://www.ncbi.nlm.nih.gov/pubmed/33494466 http://dx.doi.org/10.3390/molecules26030552 |
Ejemplares similares
-
Chromatin as a Target for the DNA-Binding Anticancer Drugs
por: Majumder, Parijat, et al.
Publicado: (2007) -
The Role of the Hippo Pathway in Melanocytes and Melanoma
por: Kim, Ji Eun, et al.
Publicado: (2013) -
Heterogeneity of expression of epithelial–mesenchymal transition markers in melanocytes and melanoma cell lines
por: Kim, Ji Eun, et al.
Publicado: (2013) -
DNA topoisomerases as molecular targets for anticancer drugs
por: Buzun, Kamila, et al.
Publicado: (2020) -
Intercalative DNA binding of the marine anticancer drug variolin B
por: Canals, Albert, et al.
Publicado: (2017)